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Introduction 
Atrial fibrillation (AF) is the most frequent 
post-coronary artery bypass grafting (CABG) 
dysrhythmia. After CABG, the reported incidence 
of AF ranged from 20 to 40%, with dysrhythmia 
typically occurring between the second and 
fourth days [1-6]. 
Although these dysrhythmias are usually 
benign, it may result in longer hospital stay due to 
hemodynamic instability and thromboembolic 
events; consequently, healthcare costs are 
increased [2,4,7,8]. 
For prophylaxis against postoperative AF, 
according to the guidelines recommendations for 
routine prophylaxis, the use of β-blockers is 
considered as "class I, level of evidence; A," while 
for prophylaxis for high-risk patients, the use of 
amiodarone is considered as "class IIa, level of 
evidence: A). On the other hand, the use of sotalol 
is considered as "class IIb, level of evidence: B" [9], 
probably due to sotalol side effect profile. 
Nystorom and colleagues [10] conducted a 
trial to compare sotalol to metoprolol in doses 
considered to provide equivalent Beta-blockade; 
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the result was a higher prevalence of 
postoperative dysrhythmia in the sotalol 
prophylaxis arm. We hypothesized that a low-dose 
sotalol regimen could be superior to metoprolol in 
reducing the incidence of high-risk postoperative 
AF. Accordingly, this study aimed to investigate 
the efficacy of prophylactic metoprolol versus low-
dose sotalol regimens to prevent high-risk atrial 
fibrillation following coronary artery bypass 
surgery. 
Patients and Methods: 
We conducted this study in the Departments 
of Cardiology and Cardiothoracic Surgery, Faculty 
of Medicine, Zagazig, and Cairo Universities. The 
study included 113 consecutive high-risk patients 
for postoperative AF (POAF) who had primary 
CABG from February 2018 to July 2020. The 
criteria for high-risk POAF were described before 
[11] and included one or more of the following: 
elder patients, large left atrium, and P-wave 
abnormality on ECG.   Patients that were in sinus 
rhythm before the procedure and who were not 
on antiarrhythmic medications were included. 
Patients who had a concomitant operation, 
uncontrolled heart failure, low left ventricular 
ejection fraction (EF) (< 45%), cardiogenic shock, 
sustained ventricular tachyarrhythmia, end-stage 
renal disease, an implanted pacemaker, or with 
contraindications to β-blockers were excluded.  
The patients were allocated to obtain either 
metoprolol 25-100 mg twice daily (Group A; n = 
59) or low-dose sotalol 40 mg twice daily (Group
B; n = 54), which was continuous for ten days after 
surgery. For new-onset AF during the study 
period, amiodarone oral and intravenous was 
given. The research complied with the Helsinki 
declaration [12] and was accepted by the 
participating centers' Medical Ethics Committee. 
All patients gave informed consent in writing. 
Technique: 
The patients underwent CABG according to 
the standard surgical technique. Patients were 
continuously monitored up to the fifth 
postoperative day. After the patients shifted to 
the ward, they were also monitored using 
telemetry. All medical, hemodynamic, and surgical 
details were gathered, and an electrocardiogram 
(ECG) was reported 24-48 hours before surgery. A 
further ECG was recorded on days 0, 1, 2, 4, and 8 
following operations and before discharging 
home. An apical and peripheral heart rate was 
checked at a 6-hour interval up to hospital 
discharge, and if AF was suspected, an additional 
12-leads ECG was obtained. After hospital 
discharge, patients were followed every two 
weeks by their referring physician, and ECG was 
obtained each visit. At the end of the six-week 
follow-up period, all data were analyzed. Two 
cardiologists, who were blinded to other data, 
reviewed the ECG records. 
The primary end-point was the frequency of 
the new-onset- POAF during the first 6-week 
follow-up. Secondary end-points were major 
adverse cardiovascular events (MACE) during the 
6-weeks follow-up. Clinically significant AF 
episodes have been identified as symptomatic AF 
episodes at a rate of ≥ 120 beats/minute. 
Statistical analysis: 
The continuous variables were expressed as 
mean ± standard deviation (SD), while discrete 
variables were expressed as numbers and 
percentages. The differences in continuous 
variables were checked for statistical significance 
by t-test or Mann-Whitney test as appropriate. 
The differences in the discrete variables were 
checked for statistical significance with the X2 test 
or Fisher exact test. 
Univariable and multivariable logistic 
regression analysis was used to identify factors 
affecting the occurrence of POAF, and odds ratio 
(OR) and 95% confidence interval (CI) were 
reported.  
All statistical comparisons were two-tailed, 
and a p-value of <0.05 was considered statistically 
significant. The statistical analysis was performed 
using SPSS 11 for windows (SPSS Inc., Chicago, 
Illinois, USA). 
Results 
The baseline, clinical, ECG, and 
echocardiographic variables are shown in Table 1. 
No statistically significant differences in age, 
gender, diabetes mellitus, hypertension, or in the
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Table 1: Baseline characteristics of the study population. Values are presented as mean ± SD or n (%). 
Metoprelol group (n = 59) Sotalol group (n = 54) p value 
I. Clinical variables 
      Age (years) 61.5 ± 7 62.5±6 0.66 
      Male gender 53 (89.8) 49 (90.7) 0.87 
      Diabetes mellitus 12 (20.3) 11 (20.4) 0.99 
      Hypertension 30 (50.8) 27 (50) 0.92 
      Dyslipidemia 36 (61) 23 (42.6) 0.05 
      Current smokers 33 (55.9) 20 (37) 0.04 
      COPD 3 (5.1) 3 (5.6) 0.75 
II. ECG variables
      p wave duration (ms) 118 ± 12 119 ± 11 0.46 
III. ECHO variables
EF 55 ± 17 58 ± 15 0.99 
MR 6 (10.2) 5 (9.2) 0.87 
LVH 5 (8.5) 4 (7.4) 0.88 
AF = Atrial Fibrillation; EF% = Ejection Fraction; MR = Mitral Regurgitation; LVH = Left Ventricular 
Hypertrophy; COPD= Chronic obstructive pulmonary disease  
criteria predicting high-risk POAF. On the other 
hand, the frequency of dyslipidemia was 
significantly higher among the metoprolol group, 
while the frequency of smoking was significantly 
higher among the sotalol group (p-value= 0.05 and 
0.04), respectively. 
Angiographic and operative variables are 
shown in Table 2. No statistically significant 
differences in the Euro-score, frequency of 
multivessel disease, reference vessel diameter, 
left internal mammary artery (LIMA) graft, vein 
graft, distal anastomosis, cardiopulmonary 
bypass, cardiopulmonary bypass time, 
endarterectomy, pericardial closure or aortic 
cross-clamp were found between the two groups. 
On the other hand, the frequency of two-vessel 
disease was significantly higher among the 
patients of the sotalol group (p-value= 0.02). The 
mean intubation time was significantly higher 
among the metoprolol group (p-value= 0.02; 
0.008), respectively. 
The postoperative, as well as 6-week follow-
up variables, are shown in Table 2. No patient 
had death, stroke, heart failure (HF), angina, 
torsade de point, or high-grade atrioventricular 
(AV) block in the two groups. On the other hand, 
the frequency of AF at follow up and the length of 
hospital stay was significantly higher among the 
metoprolol group (p-value= 0.017 and 0.001), 
respectively. 
Sotalol was more effective than metoprolol in 
prophylaxis against POAF (OR= 0.04, CI= 0.18- 
0.92). Univariable and multivariable model 
analysis for different variables predicting POAF is 
shown in Table 3. According to the multivariable 
model analysis, the predictors of POAF were: age, 
EF, and sotalol. Sotalol use was protective against 
POAF (OR= 0.49; 95% CI= 0.25 -0.97; P= 0.02). 
Discussion 
AF is the most frequent arrhythmia after CABG 
with a reported incidence between 20-40%; 
usually, its onset is between the second and 
fourth postoperative days [1,2,4-6]. 
Prevention of POAF reduces healthcare costs 
[8]. Sotalol is class III potent antiarrhythmic. Its use 
for prophylaxis for high-risk POAF is considered as 
class IIb (level of evidence = B) [9], probably due to 
the side-effect profile of sotalol. Our hypothesis of 
using low-dose sotalol to achieve prophylaxis but, 
at the same time, avoid its arrhythmia-related side 
effects was luckily effective. 
Results of our study demonstrated that in the 
prevention of high-risk POAF, low-dose sotalol is 
more effective than metoprolol. The beneficial
I
Pr
es
s
66 
Table 2: Angiographic, operative and postoperative variables of the study population. Values are presented as mean ± 
SD or n (%). 
Metoprelol group (n = 59) Sotalol group (n = 54) p value 
I. Angiographic variables 
      Euro score 4.2 ± 0.5 4.1 ± 0.6 0.96 
      Percent of 2 vessel disease 25 (42.4) 12 (22.2) 0.02 
      Percent of triple vessel disease 44 (74.5) 42 (77.8) 0.6 
      RVD 2.76 ± 0.6 2.93 ± 0.69 0.24 
II. Operative variables
      LIMA graft 0.7 ± 0.5 0.7 ± 0.5 ˃0.99 
      Vein graft 2 ± 1 2 ± 1 ˃0.99 
      Distal anastomosis 3 ± 1 3 ± 1 ˃0.99 
      CPB  47 (79.7) 43 (79.6) 0.99 
      OPCAB 12 (20.3) 11 (20.4) 0.99 
      Extra corporeal bypass time 97 ± 22 96 ± 5 0.332 
      Aortic cross-clamp time (minutes) 57 ± 15 58 ± 16 0.34 
      Intubation time (hours) 22 ± 4 20 ± 4 0.008 
      Endarterectomy 3 (5.1) 3 (5.6) 0.75 
      Pericardial closure 18 (30.5) 17 (31.5) 0.91 
  AF 35 (59.3) 20 (37) 0.017 
  Hospital stay (days) 7.5 ± 1.3 6.1 ± 1.2 < 0.001 
AF: Atrial fibrillation; RVD: Reference Vessel Diameter; LIMA: Left Internal Mammary Artery; OPCAG: Off-
Pump Coronary Artery Bypass; CPB: cardiopulmonary bypass. 
influence of sotalol can be because it is a beta-
blocker drug with significant antiarrhythmic 
properties in class III. Several reports have 
examined the prevalence of POAF sotalol 
prophylaxis. 
Burgess and coworkers [13] performed a 
meta-analysis of 14 studies involving 2,583 
patients evaluating beta-blockers or placebo. It 
showed that sotalol was more beneficial than 
other beta-blockers or placebo in minimizing 
POAF. Sotalol tends, therefore, to provide 
substantial protection compared to remaining 
beta-blockers. However, in one clinical trial, a 
higher prevalence of postoperative brady 
arrhythmias was observed in the sotalol arm in 
doses where metoprolol was considered to 
provide the equivalent beta blockage effect. 
Several patients withdrew due to side effects from 
the sotalol arm, predominantly bradycardia, and 
hypotension [14]. 
The autonomic nervous system has been 
involved in the initiation and continuation of atrial
Table 3: Univariate versus multivariate model analysis for POAF and different variables predicting its occurrence. 
Univariable analysis Multivariable analysis 
OR (95% CI) P OR (95% CI) P 
Age  60 3.25 (1.32-8.09) 0.004 1.86 (1.01-4.41) 0.03 
Sotalol use 0.4 (0.18-0.92) 0.017 0.49 (0.25-0.97) 0.02 
LV ejection fraction 2.73 (1.17-6.4) 0.001 2 (1.05-3.83) 0.02 
HTN 2.7 (1.17-6.29) 0.01 - 
P wave abnormality 2.18 (0.93-5.1) 0.04 - 
HTN: hypertension; LV: left ventricle; HTN: hypertension; POAF: postoperative atrial fibrillation 
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fibrillation. Fibrillation has been seen, to begin 
with, as an episode of a rapid extrasystole [15]. 
The proposed causes were the incidence of a 
single ectopic focus whose impulse discharge 
frequency was so fast that consistent atrial 
excitation was no longer probable. Triggered 
activity or enhanced automaticity may be the 
mechanisms that cause the phenomenon of POAF 
in setting an increased sympathetic state or high 
catecholamine level. Sympathetic activation often 
decreases atrial refractoriness in a nonuniform 
way that facilitates the continuation of atrial 
fibrillation [16]. 
In most cases, suggesting the role of 
sympathetic stimulation is evident in atrial 
fibrillation occurring for the first time shortly 
following CABG and indicates that the 
provocative stimuli will not arise any longer [17]. 
Our protocol regimen of giving the prophylaxis 
medications starting on the day of the surgery, 
maintained for ten days postoperatively, was 
suitable in the prevention of POAF because the 
dysrhythmia usually starting between the second 
and fourth postoperative days [6]. To avoid the 
marked pro-arrhythmic side effects reported in 
the survival with oral D-sotalol trial (SWORD) 
[18], sotalol was given at a low-dose regimen and 
for ten days only. 
Weber and colleagues [19] proposed that the 
use of low-dose sotalol in patients during CABG 
should be limited in the first nine days following 
the operation. Our protocol to identify the 
preoperative risk stratification of surgical patients 
for the occurrence of post-CABG AF was 
previously described [11]; their variables were 
validated by several other studies [3,4,20-23].   
The use of antiarrhythmic prophylaxis in high-risk 
situations increases the cost-effectiveness and 
safety of antiarrhythmic [24]. 
A previous randomized clinical trial had tested 
the efficiency of sotalol versus metoprolol in 
preventing high-risk POAF following CABG.  This 
study demonstrated the superiority of sotalol over 
metoprolol in the prevention of POAF. Unlike 
other studies, Parrika and associates examined 
sotalol's ability to prolong repolarization even in 
modest doses suggesting a specific class III effect 
of sotalol is present [25]. 
Low to moderate doses of sotalol is effective in 
preventing POAF following CABG. Furthermore, 
sotalol is especially effective in high-risk subgroup 
[25]. Our results demonstrated no differences 
between the two groups in MACE except longer 
hospital stay length among the metoprolol group. 
The longer hospital stay is most probably due to 
the higher frequency of POAF noticed among the 
same group (metoprolol group) that mandated 
extension of admission. Our findings of prolonged 
hospital stay among metoprolol arm agreed with 
Pfisterer and coworkers' study [22].  A double-
blinded placebo-controlled clinical randomized 
trial in patients undergoing CABG, where the low-
dose sotalol reduced the AF rate to 26%, together 
with a reduced hospital stay in the sotalol arm. 
Auer and associates [26] further investigated 
the relative effects of sotalol, metoprolol, 
amiodarone plus metoprolol versus placebo 
through a randomized, double-blinded trial in 
patients undergoing CABG. Again, they reported a 
significantly longer hospital stay in those who had 
POAF compared to those with no POAF. 
Limitations: 
Firstly, the present study has a low sample 
size. Secondly, a 6-week period is a relatively short 
follow-up period; a longer follow-up duration is 
needed to detect MACE. Thirdly, AF definition, and 
the method of its detection (using Holter device) 
is not used, definitely affected the reported 
incidence, which may be lower than that reported 
by other studies. Fourthly, it tested only the low-
dose sotalol. Testing moderate dose sotalol that 
may lead to further reduction of POAF in that high-
risk group is still needed. Finally, the POAF risk 
stratification score used in this study needs further 
testing on a wide-scale basis. However, this was 
beyond the scope of our current study. 
Conclusion 
Prophylactic low-dose sotalol could be 
superior to metoprolol for the prophylaxis of POAF 
in high-risk patients. However, Larger prospective 
multicenter randomized trials are needed to 
confirm our findings. 
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